The Future of Patient Care: Exploring Intravenous CBD for Enhanced Health

Release of whitepaper "Intravenous Cannabidiol (CBD) in Cancer: a New Frontier in motion" by Dr. Goodyear delves into the potential of cannabidiol (CBD) as a revolutionary tool for improving patient health and reducing inflammation. We'll explore CBD's history, current uses, and exciting future directions, particularly focusing on intravenous administration and its potential benefits.

A Natural Approach with a Rich History

CBD, a natural compound discovered in 1940, is one of many phytocannabinoids found in cannabis. Its use dates back an astonishing 11,700 years! Traditionally, CBD has been administered orally through tinctures, capsules, or lozenges. However, this method suffers from low bioavailability, meaning the body absorbs less CBD, requiring higher and more frequent doses.

Intravenous CBD: A Promising Delivery Method

Intravenous (IV) administration offers a potential solution. By delivering CBD directly into the bloodstream, IV theoretically increases bioavailability and may lead to enhanced symptom relief. While research on intravenous CBD is still in its early stages,  preliminary studies by PICO-IV suggest a potentially prolonged metabolic half-life, meaning the effects of CBD last longer. Historical data suggests IV delivery could have a half-life similar to inhalation (around 24-31 hours), but further research is needed to confirm this for CBD specifically.

The Potential Benefits of CBD

CBD exhibits a wide range of therapeutic effects, including pain relief, anti-nausea and vomiting control, anxiety reduction, improved sleep, and mood regulation. Additionally, CBD shows promise in treating epilepsy, asthma, and inflammation. Its potential anti-bacterial, neuroprotective, and anti-cancer properties suggest a vast array of future applications.

Intravenous CBD: A New Gold Standard?

Intravenous administration of CBD holds immense promise as a new "gold standard" for delivering this therapeutic compound. With its potential for improved bioavailability and enhanced effects, IV CBD could revolutionize patient care across various conditions.

"In my four-month experience with IV CBD in cancer patients. Only one patient required a scheduled IV CBD appointment cancellation for dehydration-related hypotension. Of the many therapies that we use in a complicated patient population over the course of 6-10 weeks, IV CBD is one of the more well-tolerated treatments."

- Dr. Goodyear.

About PICO IV Inc.
Founded in 2023, PICO IV Inc pioneered a new technology to become the world's first manufacturer of CBD IV Therapy. Committed to using the highest quality CBD with rigorous third-party testing, Pico IV sets the standard for CBD quality, transparency, and efficacy. PICO IV is currently available in a number of clinics across the US and is available for purchase by licensed providers. For more information, please visit PicoIV.com

About Dr. Nathan Goodyear.
With 15 years of experience treating complex patients with all stages and types of cancer, Dr. Goodyear, MD, MDH, ABAARM, is the Medical Director of Brio Medical. Established in 2019 in Scottsdale, Arizona, Brio-Medical is an integrative alternative cancer treatment center and immune recovery facility offering advanced, research-based integrative medical treatments for all types of cancer and accompanied chronic illnesses.

Download:  Whitepaper "Intravenous Cannabidiol (CBD) in Cancer: a New Frontier in motion" by Dr. Goodyear

Source: picoiv.com